Biologic Therapy for Autoimmune Disease: A Doctor’s Guide to What Rheumatologists and Immunologists Want Every Patient to Know in 2026
Introduction: Why Biologic Therapy Is Reshaping Autoimmune Care in 2026
Autoimmune diseases affect roughly 450 million people worldwide across more than 100 distinct disorders, from rheumatoid arthritis and lupus to inflammatory bowel disease and multiple sclerosis. For millions of these patients, biologic therapy has fundamentally changed what daily life looks like.
The numbers tell a striking story. Biologics now account for about 52% of autoimmune treatments and show efficacy rates exceeding 70% in clinical trials, yet they represent 51% of total U.S. drug spending despite making up only 5% of prescriptions. That paradox sits at the heart of the questions patients bring to their specialists every day.
This article is not a basic explainer. It is a physician-guided resource that draws on the perspectives rheumatologists and immunologists share with their patients, organized around the questions people actually ask. It addresses three gaps mainstream health sites rarely cover: which specialist to see, what the landmark 2025 ACR and BSR guidelines mean for patients, and whether a biosimilar is the right choice in 2026. The goal is complex science translated into plain language, backed by current clinical evidence.
What Is Biologic Therapy? A Plain-Language Explanation From Specialists
Biologics are large, complex molecules derived from living cells. Unlike traditional medications that broadly suppress immune activity, biologics target specific components of the immune system. That precision is why specialists favor them for moderate-to-severe disease.
In autoimmune disease, the immune system mistakenly attacks the body’s own tissues. Biologics interrupt the specific inflammatory signals driving that attack. The American College of Rheumatology explains that biologic and immunosuppressive medications target parts of the immune system to stop the inflammation causing damage in autoimmune rheumatic diseases.
Compared with conventional disease-modifying antirheumatic drugs (DMARDs) and corticosteroids, which act more broadly, biologics offer targeted intervention. The major classes patients encounter include TNF inhibitors, IL-6 inhibitors, IL-1 inhibitors, B-cell depleting agents, T-cell co-stimulation blockers, and JAK inhibitors. (JAK inhibitors are technically “targeted synthetic DMARDs,” but they are often discussed alongside biologics.) With over 120 biologic drugs currently in development, this is one of the fastest-moving fields in medicine.
The Major Classes of Biologic Therapy: What Each One Targets
Drug selection is highly individualized. Specialists weigh disease activity, prior medications, comorbidities, adverse effect profiles, cost, patient preference, and route of administration. Here is what each major class does.
TNF Inhibitors: The Foundational Class
TNF (tumor necrosis factor) is a protein that drives inflammation. TNF inhibitors block it before it can cause joint and tissue damage. Key agents include adalimumab (Humira), infliximab (Remicade), and etanercept (Enbrel).
These drugs treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. They do carry important nuances. Cleveland Clinic specialists note that TNF inhibitors carry higher risks of serious and opportunistic infections than traditional DMARDs, with etanercept carrying the lowest tuberculosis risk among them.
A major development for patients: Humira sales have declined more than 56% from their 2023 peak as biosimilar alternatives have entered the market, opening the door to far more affordable options.
IL-6 and IL-1 Inhibitors: Targeting the Cytokine Storm
Interleukins such as IL-6 and IL-1 are inflammatory messenger proteins. Blocking them reduces systemic inflammation. Key agents include tocilizumab (Actemra) and sarilumab (Kevzara) for IL-6, and anakinra (Kineret) for IL-1.
These agents treat rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis. Specialists often turn to them when TNF inhibitors fail or are contraindicated.
B-Cell and T-Cell Targeted Therapies
Rituximab depletes B cells, the cells that produce the autoantibodies driving conditions like rheumatoid arthritis, lupus, and vasculitis. Abatacept (Orencia) blocks T-cell co-stimulation, preventing T cells from activating the immune cascade.
These agents are frequently used after TNF inhibitor failure, reflecting the trial-and-error reality of biologic selection. Switching to a non-TNF targeted therapy after a TNF inhibitor stops working is increasingly supported by clinical evidence.
JAK Inhibitors: The Oral Alternative Patients Are Asking About
JAK (Janus kinase) inhibitors block intracellular signaling pathways that drive inflammation. Crucially, they are taken as pills rather than injections. Key agents include tofacitinib (Xeljanz), baricitinib (Olumiant), and upadacitinib.
That oral convenience explains their appeal for patients who struggle with injections or infusions, and adoption increased by 20% between 2021 and 2025. However, JAK inhibitors carry a specific safety profile, including cardiovascular and clotting concerns in higher-risk patients, that rheumatologists weigh carefully. The 2025 British Society for Rheumatology (BSR) axial spondyloarthritis guideline recommends JAK inhibitors alongside TNF and IL-17 inhibitors for active disease.
Rheumatologist or Immunologist? A Specialist-Routing Guide for Autoimmune Patients
“My doctor said I need a specialist, but which one?” is among the most common patient questions.
Rheumatologists specialize in musculoskeletal and systemic autoimmune diseases: rheumatoid arthritis, lupus, ankylosing spondylitis, psoriatic arthritis, vasculitis, and Sjögren’s syndrome. They are the primary prescribers of most biologics for these conditions.
Clinical immunologists focus on immune system dysfunction, including primary immunodeficiency disorders, allergic diseases with autoimmune overlap, and complex cases where the immune system’s behavior is the central diagnostic question.
A practical framework: if symptoms primarily involve joints, skin, kidneys, or systemic inflammation with a known autoimmune diagnosis, a rheumatologist is typically the first stop. If the immune system appears dysregulated in ways that do not fit a clear diagnosis, or if recurrent infections accompany autoimmune features, an immunologist may be the right entry point. Many complex patients are co-managed by both. Gastroenterologists, dermatologists, and neurologists also prescribe biologics within their respective domains, covering IBD, eczema, and MS.
Primary care physicians play a critical referral role, so patients should advocate for a specialist referral when symptoms suggest autoimmune disease. A practical tip: when scheduling, ask whether the specialist has experience prescribing biologics for the specific condition in question.
What the 2025 Landmark Guidelines Mean for Patients: A Plain-Language Translation
Guidelines represent the consensus of leading specialists and directly influence what physicians recommend. Two recent updates may affect treatment plans significantly.
The 2025 ACR Lupus Guidelines: The Biggest SLE Update in 26 Years
The 2025 ACR Guideline for Systemic Lupus Erythematosus is the first comprehensive update since 1999, representing a generational shift in lupus care. Three changes matter most for patients:
- Earlier biologics. The guideline emphasizes introducing biologic immunosuppressive therapies early rather than waiting for disease to worsen. Patients may be offered biologics sooner.
- New agents included. Belimumab (Benlysta) and anifrolumab (Saphnelo) are now formally part of the treatment algorithm. Lupus patients should ask whether these newer biologics are appropriate for their case.
- Steroid minimization. The guideline explicitly recommends minimizing long-term corticosteroid exposure, reflecting evidence of steroid-related organ damage over time.
The practical takeaway is that the conversation about biologics should now happen earlier, and patients should feel empowered to initiate it.
The 2025 BSR Axial Spondyloarthritis Guidelines: What Patients With AS and nr-axSpA Need to Know
Axial spondyloarthritis (axSpA) is inflammatory arthritis primarily affecting the spine and sacroiliac joints, including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). The 2025 BSR guideline recommends TNF, IL-17, or JAK inhibitors for active disease that has not responded to non-pharmacological management and conventional treatments.
Importantly, response is assessed using validated disease activity indices three to four months after starting therapy. If a biologic is not working within that window, switching is appropriate and evidence-supported. Patients on an axSpA biologic for several months without meaningful improvement have clear backing to discuss switching with their rheumatologist.
Is a Biosimilar Right for You? The 2026 Patient Guide Mainstream Health Sites Are Not Writing
“My doctor mentioned a biosimilar. Is it as good as the original drug?”
Biosimilars are highly similar versions of already-approved biologics, developed after the original’s patent expires, much like generic pills relate to brand-name pills, though the manufacturing is far more complex. The FDA requires biosimilars to demonstrate no clinically meaningful differences in safety, purity, and potency from the reference biologic. They are not identical, but they are not inferior.
The cost case is compelling. Biosimilars are roughly 60% cheaper than originators and have delivered more than $30 billion in cumulative U.S. savings since 2015. As of March 2026, the FDA has approved 82 biosimilars and released streamlined guidance that could save developers up to 50% of pharmacokinetic study costs (approximately $20 million per program), accelerating the affordable pipeline.
Humira illustrates the shift. Once the world’s best-selling drug, its sales have fallen more than 56% from their 2023 peak as multiple biosimilars entered the market at lower prices. Some biosimilars are designated “interchangeable” by the FDA, meaning a pharmacist can substitute them without physician intervention. Patients should confirm whether their biosimilar carries that designation.
Practical guidance: patients should ask their specialist whether a biosimilar version of their current or planned biologic exists, ask their insurer whether it is preferred on the formulary, and inquire about patient assistance programs if cost remains a barrier. The biosimilar market for autoimmune drugs is growing at a CAGR of 9.80% through 2033, with 118 biologics facing patent expiries between 2025 and 2034. More affordable options are on the way.
How Specialists Select the Right Biologic: The Decision Framework Patients Rarely See
Biologic choice is not arbitrary. It follows a structured framework that patients can understand and participate in. Specialists weigh disease activity and severity, the specific diagnosis and affected organs, prior treatment history and response, comorbidities (cardiovascular disease, diabetes, malignancy history, recurrent infections), potential adverse effects, route of administration, cost and coverage, and patient lifestyle and preferences.
The honest reality is that the field still relies significantly on clinical experience and sequential trials. Patients may need to try more than one biologic before finding the right fit, and that is a normal part of the process, not a failure. Encouragingly, personalized medicine now influences treatment decisions in nearly 28% of autoimmune cases, and biomarker-based therapies have improved patient outcomes by 35% in clinical trials. Genomic testing adoption rose 40% between 2020 and 2025.
A practical tip: patients should arrive at appointments with a list of previous medications and their outcomes, current comorbidities, and preferences regarding injections versus oral medications. The best choice is made collaboratively.
Understanding the Risks: What Specialists Screen for Before Starting a Biologic
Pre-treatment screening exists because biologics modulate the immune system, which can unmask latent infections or increase susceptibility to new ones. This is not a reason to avoid biologics; it is a reason to trust the process.
Standard screening includes tuberculosis testing (TNF inhibitors can reactivate latent TB), hepatitis B and C testing, review of malignancy history, cardiovascular risk assessment (especially relevant for JAK inhibitors), and a pregnancy and family-planning discussion. Biologic therapy is associated with increased risk of serious bacterial, viral, and fungal infections, a real but manageable risk with proper monitoring. Cleveland Clinic guidance notes that etanercept carries the lowest TB risk among TNF inhibitors, a nuance that may guide selection in patients with TB exposure.
Patients should receive all recommended vaccines before starting biologic therapy, as live vaccines are generally contraindicated once immunosuppressive biologics begin. Questions about distrust amid vaccination are common, and specialists can address concerns directly. In rare cases, biologics can trigger other autoimmune phenomena, which specialists monitor for. These risks are precisely why specialist oversight matters.
Biologics During Pregnancy: What Rheumatologists Want Expecting Patients to Know
A fact that surprises many patients: in a large cohort study spanning 2011 to 2021, about 72% of pregnant women with autoimmune conditions continued biologic therapy during pregnancy, with TNF inhibitors the most frequently used class. Uncontrolled autoimmune disease during pregnancy carries serious risks to both mother and fetus, so the decision to continue or stop is rarely straightforward.
Rheumatologists and maternal-fetal medicine specialists weigh continued exposure against the risk of disease flare. Most TNF inhibitors cross the placenta, particularly in the third trimester. Certolizumab pegol (Cimzia) is an exception with minimal placental transfer, which influences prescribing for patients planning pregnancy. Some biologics are considered compatible with breastfeeding, a topic patients should discuss explicitly with their specialist.
Critical guidance: patients should not stop a biologic without consulting their rheumatologist, since abrupt discontinuation can trigger a flare. Preconception counseling should be scheduled if pregnancy is planned. Attention to nutritional needs during pregnancy is also an important part of overall care for patients managing autoimmune disease while expecting.
The Cost and Access Reality: Navigating Insurance, Assistance Programs, and the Biosimilar Opportunity
Branded biologics can cost $10,000 to $30,000 per year, and biologics account for 51% of total U.S. drug spending despite representing just 5% of prescriptions. The reasons include complex manufacturing, substantial development costs, and historically limited competition, though biosimilars are changing that landscape.
Specialists help patients navigate several access pathways: commercial insurance prior authorization (PA), Medicare Part B (for infused biologics) versus Part D (for self-injected biologics), manufacturer patient assistance programs for the uninsured or underinsured, and co-pay assistance cards for the commercially insured. PA requirements can delay initiation by weeks or months, and many specialist offices have staff dedicated to navigating them.
A practical tip: patients should ask whether the specialist’s office has a patient navigator, financial counselor, or social worker. The 60% savings available through biosimilars represents a meaningful access improvement, so patients should ask proactively whether one is available and covered. North America leads global autoimmune treatment with 38% market share, reflecting both high disease burden and significant healthcare investment.
When Biologics Stop Working: Understanding Non-Response and What Comes Next
Non-response is well recognized in clinical practice. Primary non-response means the biologic never works; secondary non-response means it works initially and then loses effectiveness. One mechanism behind secondary non-response is immunogenicity, where the body develops anti-drug antibodies (ADAs) that reduce effectiveness over time.
Specialists respond with dose optimization, the addition of a conventional DMARD such as methotrexate to reduce immunogenicity, or switching to a biologic with a different mechanism. Switching to a non-TNF targeted therapy after TNF inhibitor failure is increasingly supported by evidence, and the 2025 BSR guideline’s three-to-four-month assessment window provides a clear framework for when to consider it.
Patients should report inadequate response promptly rather than waiting, since earlier switching leads to better outcomes. Therapeutic drug monitoring, which measures biologic and ADA levels in the blood, can help specialists determine whether non-response is due to immunogenicity or another cause.
The Horizon: Next-Generation Therapies Beyond Traditional Biologics
These advances represent forward-looking context rather than immediate options for most patients, but they signal where the field is heading.
CAR-T cell therapy, originally developed for cancer, is now being explored for severe, refractory autoimmune conditions, with remarkable early results in lupus. Bispecific antibodies can target two inflammatory pathways simultaneously, and microbiome-based interventions are in early development as research links gut bacteria to autoimmunity. CAR-Treg therapy builds on the 2025 Nobel Prize in Medicine for the discovery of the FOXP3 gene, which allows scientists to transform T cells into regulatory T cells (Tregs) that target autoreactive B cells, a potential paradigm shift in treatment.
Pipeline momentum continues: in April 2026, the FDA granted Priority Review to nipocalimab for warm autoimmune hemolytic anemia, and AbbVie submitted for subcutaneous risankizumab as Crohn’s disease induction therapy. Current biologics remain the standard of care, but the field is advancing rapidly, and patients should stay engaged with their specialists about emerging options.
Questions to Ask Your Rheumatologist or Immunologist at the Next Appointment
This take-to-the-appointment checklist distills the specialist perspectives throughout this guide:
- Is biologic therapy appropriate for my condition and disease activity right now? Establishes where the patient is in the treatment algorithm.
- Which biologic class do you recommend, and why? Invites the specialist to explain their reasoning.
- Is a biosimilar version available, and would it be appropriate? Opens the cost and access conversation.
- What does pre-treatment screening involve, and how long will it take? Sets a realistic timeline.
- What side effects should I watch for, and when should I call? Establishes safety monitoring expectations.
- How will we know if this biologic is working, and when would we consider switching? Aligns on response assessment.
- Are there vaccines I should get before starting? Addresses the vaccination window.
- If I am planning a pregnancy, how does that affect my options? Opens the family planning conversation.
- What financial resources are available if cost is a concern? Normalizes the cost conversation.
- Are there clinical trials or emerging therapies I should know about? Keeps the door open to next-generation options.
Conclusion: Partnering With a Specialist for Personalized Biologic Care
Biologic therapy has transformed autoimmune disease management, and the field is advancing rapidly. Navigating it successfully requires an informed partnership between patient and specialist. Patients now have a clearer framework for which specialist to see, a plain-language understanding of the 2025 ACR and BSR guidelines that may affect their care, and the knowledge to discuss biosimilars with confidence.
The complexity is real. There is no one-size-fits-all biologic, costs remain a barrier for many, and the journey may involve trial and adjustment. Yet it is a journey worth taking, supported by a steadily improving evidence base. The most important step is engaging with a qualified rheumatologist or immunologist, arriving prepared with questions, and advocating for a plan that reflects both clinical evidence and personal priorities. With over 120 biologics in development, 82 biosimilars approved, and next-generation therapies on the horizon, the outlook for autoimmune patients in 2026 is more promising than at any point in history.
Find a Specialist and Stay Informed With Top Doctor Magazine
Top Doctor Magazine connects readers with specialist profiles and in-depth physician interviews that translate clinical expertise into patient-friendly guidance, the same physician-guided perspective that informed this article. Readers can explore profiles of rheumatologists and immunologists who are leaders in biologic therapy for autoimmune disease.
To stay current on autoimmune treatment advances, new biologic approvals, and biosimilar developments, subscribe to the free Top Doctor Magazine biweekly newsletter. Readers who have benefited from the care of a rheumatologist or immunologist are also encouraged to nominate that physician for a Top Doctor Magazine feature or award.
Visit topdoctormagazine.com to read physician profiles, access health resources, and subscribe to stay informed on the medical advances that matter most.
